Physician profile
Taletha K Brown
NPI 1689181372
$1,815.03
in general payments reported to CMS, 2019-2025
12 companies · $621 in 2025
The $621 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $787 · 2024: $288 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.61 | 2023-2025 | |
| Viiv Healthcare Company | $319.99 | 2023-2025 | Apretude |
| Vanda Pharmaceuticals INC. | $273.29 | 2022-2023 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $192.65 | 2023-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Glaxosmithkline, LLC. | $149.35 | 2023-2025 | Penmenvy, Bexsero, Pediarix |
| Janssen Pharmaceuticals, INC | $145.92 | 2025 | Invega Sustenna |
| Medtronic, INC. | $133.91 | 2024 | Signia |
| Hologic Sales and Service, LLC | $37.32 | 2023-2025 | Aptima |
| Exact Sciences Corporation | $32.29 | 2025 | Cologuard Collection Kit |
| Organon LLC | $27.92 | 2023 | Nexplanon |
| Alkermes, INC. | $22.48 | 2023 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taletha Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.